Senzime Valuation Multiples

Senzime Overview

About Senzime

Senzime AB is a medical device company providing patient monitoring systems. Its portfolio comprises systems for patient monitoring of neuromuscular function and breathing, typically during and after surgery, and for the intensive care sector. TetraGraph is a system based on EMG technology for neuromuscular monitoring during surgical procedures. ExSpiron 2Xi is a non-invasive monitoring system of respiratory volume and minute ventilation used for in and out patient care. The company operates in Sweden, Germany and the USA. It derives revenue through sales of monitors and associated disposable sensors to hospitals and clinics.

Founded

1999

HQ

Employees

54

Website

senzime.com

Sectors

Medical DevicesHealth Data & AnalyticsHealthTechDeepTech

Financials (LTM)

Revenue: $14M

EBITDA: ($9M)

EV

$88M

Valuation Multiples

Multiples.vc

Start free trial

Senzime Financials

Senzime reported last 12-month revenue of $14M and negative EBITDA of ($9M).

In the same LTM period, Senzime generated $6M in gross profit, ($9M) in EBITDA losses, and had net loss of ($13M).

Senzime P&L

In the most recent fiscal year, Senzime reported revenue of $12M and EBITDA of ($11M).

Senzime expects next 12-month revenue of XXX and NTM EBITDA of XXX

Senzime Stock Performance

Senzime has current market cap of $94M, and enterprise value of $88M.

Senzime's stock price is $0.60.

Senzime Valuation Multiples

Senzime trades at 6.3x EV/Revenue multiple, and (9.8x) EV/EBITDA.

Senzime Financial Valuation Multiples

As of April 19, 2026, Senzime has market cap of $94M and EV of $88M.

Equity research analysts estimate Senzime's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Senzime has a P/E ratio of (7.4x).

Senzime Margins & Growth Rates

Senzime's revenue in the last 12 month grew by 60%.

Senzime's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.3M for the same period.

Senzime's rule of 40 is 49% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Senzime's rule of X is 155% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Senzime Public Comps

See public comps and valuation multiples for other Medical Devices and Health Data & Analytics comps.

Senzime M&A Activity

Senzime acquired XXX companies to date.

Last acquisition by Senzime was on XXXXXXXX, XXXXX. Senzime acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Senzime Investment Activity

Senzime invested in XXX companies to date.

Senzime made its latest investment on XXXXXXXX, XXXXX. Senzime invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).